- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
This week, we submitted comments relating to the efficacy and medical usefulness of cannabis as a medical treatment. In early April, the Food and Drug Administration (FDA) issued a notice in the federal register asking for public comments on cannabis and its derivatives. These comments will help inform the response of the United States to the World Health Organization in potentially reclassifying cannabis.
Much like in the United States, under international treaties, cannabis is placed in the most restrictive classifications. The Single Convention on Narcotic Drugs of 1961, which is equivalent to the global version of the Controlled Substances Act classifies cannabis as a Schedule IV drug, which has the characteristics of being liable to abuse and producing ill effects which are not set off by substantial therapeutic advantages.
ASA’s comments focus on the fact that since the original international classification of cannabis, there have been thousands of research studies that were not incorporated into the decision-making process when cannabis was originally scheduled under United Nations protocol. ASA’s comments also include studies from the National Academies of Sciences, Engineering and Medicine, The British Parliament, and International Cannabis and Cannabinoid Institution.
This call for comments marks an expansion on the WHO’s previous call for comment on cannabidiol only.
You can submit your own comments here. The deadline is tonight (April 23, 2018) 11:59 PM EST.